Hepatitis-associated Aplastic Anaemia in Children

Area of Science:

• Pediatric Hematology
• Hepatology
• Transplantation Medicine

Background:

• Idiopathic acute liver failure (IALF) in children poses a significant risk for developing life-threatening bone marrow failure (BMF).
• Hepatitis-associated aplastic anemia (HAAA) is a critical complication in pediatric IALF patients.
• Understanding HAAA's development, therapy, and prognosis is vital for patient management.

Purpose of the Study:

• To describe the clinical course, treatment strategies, and outcomes of children with HAAA.
• To compare the prognosis of HAAA with isolated acquired aplastic anemia (SAA).
• To identify key factors influencing survival in pediatric HAAA.

Main Methods:

• Retrospective analysis of 18 pediatric HAAA cases (1984-2017).
• Comparison with data from patients with isolated SAA.
• Review of treatments including liver transplantation (LTx), immunosuppressive therapy (IST), and hematopoietic stem cell transplantation (HSCT).

Main Results:

• Fifteen HAAA patients met severe aplastic anemia (SAA) criteria; 11 underwent LTx, 6 recovered without it.
• BMF signs (thrombocytopenia, leucocytopenia) preceded LTx in all cases.
• Eight patients achieved hematological remission, 6 received HSCT; 7 died from infections/bleeding. Isolated SAA patients had a 73% remission rate with IST alone.

Conclusions:

• Early and regular blood count monitoring (0-22 days post-onset) is essential for IALF patients.
• Aggressive treatment combining LTx, IST, and HSCT shows promise in improving HAAA prognosis.
• The etiology of HAAA remains largely unknown despite extensive investigations.